Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR ...
Bowel cancer is the fourth most common cancer in the UK, and the second most common cause of cancer death. The disease falls ...
Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Israel Prize winner Prof. Michal Schwartz says her team's work fighting Alzheimer's can lead to treatments that boost immune ...